CA2861565C - Vaccin a base de cellules cancereuses autologues - Google Patents

Vaccin a base de cellules cancereuses autologues

Info

Publication number
CA2861565C
CA2861565C CA2861565A CA2861565A CA2861565C CA 2861565 C CA2861565 C CA 2861565C CA 2861565 A CA2861565 A CA 2861565A CA 2861565 A CA2861565 A CA 2861565A CA 2861565 C CA2861565 C CA 2861565C
Authority
CA
Canada
Prior art keywords
cells
mhcii
cancer
cancer cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861565A
Other languages
English (en)
Other versions
CA2861565A1 (fr
Inventor
Fernando Thome Kreutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Cellvax Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellvax Therapeutics Inc filed Critical Cellvax Therapeutics Inc
Priority claimed from PCT/BR2013/000047 external-priority patent/WO2013106895A1/fr
Publication of CA2861565A1 publication Critical patent/CA2861565A1/fr
Application granted granted Critical
Publication of CA2861565C publication Critical patent/CA2861565C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Un vaccin à base de cellules cancéreuses autologues comprend des cellules cancéreuses qui expriment à la fois MHCI et MHCII sur leur surface. MCHI présente un antigène du cancer et MHCII présente un antigène du non-soi. Selon un aspect, cette invention concerne un procédé de production de cellules cancéreuses immunogènes isolées, ce procédé consistant à induire l'expression de MHCII sur des cellules cancéreuses isolées chez un sujet; incuber les cellules cancéreuses avec un antigène du non-soi de sorte que ce dernier ne se lie pas à MHCII exprimé, et tuer les cellules cancéreuses.
CA2861565A 2012-01-20 2013-01-18 Vaccin a base de cellules cancereuses autologues Active CA2861565C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589123P 2012-01-20 2012-01-20
US61/589,123 2012-01-20
PCT/BR2013/000047 WO2013106895A1 (fr) 2012-01-20 2013-01-18 Vaccin à base de cellules cancéreuses autologues

Publications (2)

Publication Number Publication Date
CA2861565A1 CA2861565A1 (fr) 2013-07-25
CA2861565C true CA2861565C (fr) 2025-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US12016910B2 (en) Antigenic peptides for prevention and treatment of cancer
US12263210B2 (en) Immunogenic compounds for cancer therapy
ES2965957T3 (es) Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer
US12059460B2 (en) Immunogenic compounds for cancer therapy
US20160228524A1 (en) Autologous cancer cell vaccine
JP2017509642A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
CN105435218A (zh) 预防乳腺癌复发的疫苗
CA2861565C (fr) Vaccin a base de cellules cancereuses autologues
Choi et al. α-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors
HK1203817B (zh) 自体癌细胞疫苗
Gernsback et al. Overview of CNS Vaccines—Pediatrics
US20180055920A1 (en) Vaccine, therapeutic composition and methods for treating or inhibiting cancer
Colombo Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti-Interleukin 10 Receptor Antibody